Received Apr 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | W022942 | — |
No adverse event; regarding an expired administration of a dose of MMR II; Information has been received from Business Partner/CRO on 24-Apr-2025. This spontaneous report was received from a/an Nurse and refers to a(n) patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 16-Apr-2024, the patient started therapy with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), (lot #W022942, expiration date: 05-Apr-2024) 0.5 mL (0.5 mL / Two dose series),. On an unknown date, the patient started therapy with sterile diluent (MERCK STERILE DILUENT), (indication, expiration date, and lot # were not reported). The patient started therapy with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), for the treatment of Prophylaxis. On 16-Apr-2024, the patient experienced regarding an expired administration of a dose of MMR II. On an unknown date, the patient experienced No adverse event. At the reporting time, the outcome of regarding an expired administration of a dose of MMR II and No adverse event was unknown. The action taken with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live and sterile diluent was reported as not applicable.
Sterile diluent